3160 PORTER DR., PALO ALTO, CA
Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
Reports Second Quarter 2026 Financial Results and Corporate Updates
Announces FDA Acceptance of NDA for Encaleret for ADH1
Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
Director Resignation - Dr. Randal W. Scott Steps Down from Board
FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
Submits NDA to FDA for Encaleret for Individuals Living with ADH1
News
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Prospectus filed pursuant to Rule 424(b)(7)